Key Insights

Highlights

Treatment Research

2 treatments under study, led by Capecitabine

Related Conditions

Often studied with 13 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 1 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

1Total
Phase 1 (1)

Trial Status

Withdrawn1

Clinical Trials (1)

Showing 1 of 1 trials
NCT02915172Phase 1Withdrawn

Lenvatinib and Capecitabine in Patients With Advanced Malignancies

Showing all 1 trials

Research Network

Common Treatments

  • Capecitabine1
  • Lenvatinib1

Active Sponsors

  • Eisai Inc.1
  • M.D. Anderson Cancer Center1

Top Investigators

Related Conditions

  • Malignant Neoplasm Of Breast1
  • Malignant Neoplasms Of Male Genital Organs1
  • Malignant Neoplasms Of Urinary Tract1
  • Malignant Neoplasms Of Illdefined Secondary And Unspecified Sites1
  • Malignant Neoplasms Of Lip Oral Cavity And Pharynx1

Activity Timeline